Oncotarget

Withdrawal Notice

This paper was originally published in Oncotarget Advance Online Publications on 01/03/2018.
In compliance with Oncotarget's withdrawal policy, the paper was withdrawn in its entirety. It will not appear in Oncotarget internal or any external indexes or archives.

Research Papers:

Synthetic splitting receptor-based controllable switch to improve the safety of EGFRvIII+ CAR-T cells for immunotherapy of glioblastoma

Yan Zheng _, Xiu-Ling Li, Xiang-Dong Sun, Bing-Yong Zhang, Puja Gupta, Albert J. Wong, Tian-Fang Li and Shuang-Yin Han _

 

Yan Zheng1,*, Xiu-Ling Li1,*, Xiang-Dong Sun1, Bing-Yong Zhang1, Puja Gupta2, Albert J. Wong2, Tian-Fang Li3 and Shuang-Yin Han1

1 Translational Research Center, People’s Hospital of Henan Province, Zhengzhou University, Zhengzhou, China

2 Brain Tumor Research Laboratories, Department of Neurosurgery, Stanford University Medical Center, Stanford, CA, USA

3 The First Affiliated Hospital of Zhengzhou University, Zhengzhou, P.R. China

* The first two authors contribute equally to this work

Correspondence to:

Shuang-Yin Han, email: [email protected]

Tian-Fang Li, email: [email protected]

Keywords: chimeric antigen receptor; regulation; glioblastoma

Received: July 14, 2017    Accepted: October 30, 2017    Epub: January 03, 2018


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23908